Merger activity increased last week with five new deals announced and five deals closing.
Deal Statistics:
New Deals:
- The acquisition of Dova Pharmaceuticals (DOVA) by Swedish Orphan Biovitrum AB (BIOVF) for $915 million. Under the terms of the agreement, Dova stockholders will be offered an upfront payment for $27.50 per share in cash, along with one non-tradeable Contingent Value Right ((CVR)) that entitles them to an additional $1.50 per share in cash upon regulatory approval of DOPTELET for the treatment of chemotherapy-induced thrombocytopenia ((CIT)), representing a total potential consideration of $29.00 per share. We are